Medlab Clinical ( (AU:MDC) ) just unveiled an announcement.
Medlab Clinical Limited held its 2024 Annual General Meeting on February 13, 2025, where key resolutions were voted upon by stakeholders. The re-election of Director Edmond Tan was successfully carried, while the adoption of the remuneration report did not pass. The results of the AGM may influence the company’s governance and strategic direction, impacting its stakeholders and market positioning.
More about Medlab Clinical
Medlab Clinical Limited operates in the biotechnology industry, focusing on the development and commercialization of therapeutic products. The company is engaged in research and development of innovative medicines, with a strong emphasis on leveraging biotechnology to improve patient outcomes.
Average Trading Volume: 10,000
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $9.9M
Find detailed analytics on MDC stock on TipRanks’ Stock Analysis page.